FocusDrug Discovery
Paying for innovation: Reimbursement incentives for antibiotics
- 1Faculty of Arts and Sciences, Harvard University, Cambridge, MA 02138, USA.
- 2The Blackstone Group, London W1J 5AL, UK.
- 3Radcliffe Institute for Advanced Study, Harvard University, Cambridge, MA 02138, USA.
- 4Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02120, USA.
- ↵*Corresponding author. E-mail: tjhwang{at}post.harvard.edu (T.J.H.); akesselheim{at}partners.org (A.S.K.)
See allHide authors and affiliations
Science Translational Medicine 25 Feb 2015:
Vol. 7, Issue 276, pp. 276fs9
DOI: 10.1126/scitranslmed.aaa1429
Vol. 7, Issue 276, pp. 276fs9
DOI: 10.1126/scitranslmed.aaa1429
Thomas J. Hwang
1Faculty of Arts and Sciences, Harvard University, Cambridge, MA 02138, USA.
2The Blackstone Group, London W1J 5AL, UK.
Daniel Carpenter
1Faculty of Arts and Sciences, Harvard University, Cambridge, MA 02138, USA.
3Radcliffe Institute for Advanced Study, Harvard University, Cambridge, MA 02138, USA.
Aaron S. Kesselheim
4Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02120, USA.
